Data as of Apr 17
| +2.46 / +1.87%|
Allergan, Inc. operates as a global healthcare company. It engages in the developing and commercializing innovative specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries. The company operates through two business segments: Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a broad range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, retinal diseases and ocular surface disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis and eyelashes; and over-the-counter skin care products and urologic products. The Medical Devices segment produces a broad range of medical devices, including breast implants for augmentation, revision and reconstructive surgery; obesity intervention products, including the Lap-Band System and the Orbera Intragastric Balloon System and facial aesthetics products. Its products are sold to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers and medical practitioners. The company was founded by Gavin S. Herbert in 1950 and is headquartered in Irvine, CA.
|David E. I. Pyott||Chairman & Chief Executive Officer|
|Douglas S. Ingram||Executive VP-Europe, Africa & Middle East Region|
|Jeffrey L. Edwards||Chief Financial Officer & EVP-Business Development|
|Raymond H. Diradoorian||Executive VP-Global Technical Operations|
|Scott M. Whitcup||Chief Scientific Officer & Executive VP-Research|